COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
Colchicine study #2 of 9
8/12 Late treatment study
Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12) (Peer Reviewed)
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Source   PDF   Share   Tweet
RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.

Lopes et al., 8/12/2020, Double Blind Randomized Controlled Trial, Brazil, South America, peer-reviewed, 34 authors.
risk of death, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 36 (0.0%), control 2 of 36 (5.6%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 50.0% lower, RR 0.50, p = 0.67, treatment 2 of 36 (5.6%), control 4 of 36 (11.1%).
oxygen time, 38.5% lower, relative time 0.62, treatment 36, control 36.
hospitalization time, 22.2% lower, relative time 0.78, treatment 36, control 361.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 9 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary; multiple approaches are required to cover all people and all existing and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images